Products

Built multiple sets of modular, multi-functional intelligent drug automatic synthesis platform

18F-SDM-8 material

Keywords: synthetic equipment disposable consumables

Classification:

Tracers

Hotline:

0571-87701916

admin-dept@one-pfm.com

Consulting

18F-SDM-8 material

Graphic Details

18F-SDM-8 material

1. Drug name (generic name, chemical name, English name, Pinyin, if there is a customized name, the basis of naming should be explained)

Generic name: 18F-SDM-8

Chemical name: (R)-4-(3-Fluoro-5-(fluorine-18F) phenyl)-1-((3-methylpyridin-4-yl) methyl) pyrrolidin-2-one

Pinyin: (R)-4-(3-fú - 5-(fú - 18F)běn jī)-1-((3-jiǎ jī bǐ dìng - 4-jī)jiǎ jī)bǐ luò wán - 2-tóng

2. Chemical structure, molecular weight and molecular formula of the drug

chemical constitution:

Molecular weight: 317

Molecular formula: C₁₈H₁₉F₂N₂O

3. Basis of the topic (literature on the development and application of this product at home and abroad)

Foreign development and application

Research: Abroad, the 18F-SDM-8 is being studied as a novel positron emission tomography (PET) radiotracer. Studies on its synthesis and in vivo evaluation have shown that it exhibits high binding affinity for synaptic vesicle glycoprotein 2A (SV2A) in vitro binding assays (Ki =0.58 nM), with high molar activity (241.7 MBq/nmol) and high radiochemical purity (>98%). In studies using rhesus monkey brains, it demonstrated high uptake, with a peak standardized uptake value (SUV) greater than 8, and rapid reversible kinetics. Replacement and blockade studies with levetiracetam and 11C-UCB-J confirmed its reversible and specific binding to SV2A.
Application: Primarily focuses on neurodegenerative diseases and mental disorders. Due to its ability to target SV2A, synaptic structure disruption and alteration are associated with various brain diseases such as Alzheimer's disease, epilepsy, depression, and schizophrenia. The 18F-SDM-8 is expected to become a biomarker for measuring synaptic density, aiding in the diagnosis and assessment of these conditions. Additionally, in multimodal combined imaging studies, when used in conjunction with other tracers (such as 18F-FDG), it can explore the spatiotemporal relationships between different neuropathological events, elucidating the pathological processes of neurodegenerative diseases.

Domestic development and application

Development: There are also relevant researches on 18F-SDM-8 in China, and the synthesis process may be optimized to meet the quality and quantity requirements of preclinical research and future clinical application.
Application: Studies have utilized 18F-SDM-8 for imaging in rat temporal lobe epilepsy models. By injecting alginate to induce epilepsy in rats and performing 18F-SDM-8 and 18F-FDG microPET/CT imaging at different stages (acute, latent, and chronic), the asymmetry index (AI) was calculated to evaluate its ability to identify epileptic foci. The results showed that there were statistically significant differences in AI between the hippocampus of the epilepsy group and the control group at different imaging times. Moreover, the imaging agent exhibited asymmetric uptake in the epilepsy group, consistent with pathological staining results, indicating its potential for use in detecting epileptic foci.

4. Instructions for drugs

[Drug Name]

Generic name: 18F-SDM-8

Chemical name: (4R)-4-(3-(¹⁸F)fluoro-5-fluorophenyl)-1-[(3-methylpyridin-4-yl)methyl]pyrrolidin-2-one (4R)-4-(3-(¹⁸F)fluoranyl-5-fluorophenyl)-1-[(3-methylpyridin-4-yl)methyl]-pyrrolidin-2-one

English name: 18F-Sdm-8

Pinyin: shiba F-S-D-M-ba

[element]

The main component and its chemical name are: synaptic vesicle glycoprotein 2A (SV2A)

Its structural formula is:

[shape and properties]

This product is a clear liquid of colorless or yellowish.

[Indications] Epileptic lesion localization; focal cortical dysplasia (FCD) lesion detection; assessment of synaptic density in central nervous system degenerative diseases; other neurological disease research.

[18F-Sdm-8 PET/CT brain imaging process]

1. Preparations before inspection

Diet and medication management:

Avoid strenuous exercise within 24 hours before the test and fast for 4-6 hours (water is allowed) to reduce blood sugar interference.

Diabetic patients should control blood glucose in advance (fasting blood glucose is recommended to be less than 11 mmol/L), and adjust the use time of hypoglycemic drugs when necessary.

Medical history collection and contraindication screening:

Previous imaging reports (such as MRI, CT), pathological results and medication records are required.

Make sure there is no claustrophobia, severe pain or agitation that prevents you from cooperating with the test.

Environment and clothing requirements:

Before the examination, replace the clothes without metal ornaments and remove dentures, hair clips and other interfering objects.

Keep the environment warm to avoid cold stimulation that causes brown fat uptake of the imaging agent.

2. Injection of radioactive drugs and resting period

Injection of drug:

18F-SDM-8 was injected intravenously (the dose was adjusted according to body weight and equipment requirements), and the patient was kept sitting or lying down after injection.

Silent waiting:

After injection, the patient should rest in a dark and quiet environment for 45-60 minutes to avoid talking, chewing or mental activity to ensure that the imaging agent is evenly distributed in the brain.

Drink water in moderation to promote the metabolism of imaging agents and empty the bladder before examination.

PET/CT acquisition: The scan must be performed exactly 50 minutes after the injection of the contrast agent. The static scan duration is 50 minutes post-injection, with a collection time of 20 minutes. The dynamic acquisition time ranges from 0 to 70 minutes. The acquisition parameters and reconstruction methods for CT and PET should be consistent with those used for brain 18F-FDG imaging. Strict control over the injection time and scan duration is required, and the scan times must be meticulously recorded.

Image interpretation and analysis: timely interpretation of images.

Report: Report in time.

Follow-up: 18F-Sdm-8 and 18F-FDG brain imaging should be performed at least 10 half-lives apart (or 20 hours).

This product is for use only in medical units with a Radioactive Drug Use License.

[untoward effect]

Not yet found.

[taboo]

Not yet found.

[matters need attention]

If the product changes color or becomes cloudy, stop using it.

This product is only for use in medical units with a radioactive Drug Use License.

[Pregnant and lactating women]